Biotechnology Innovation Organization· @IAmBiotech · X·· 18 天前精选AI 评分60
AI 导读
FDA启动罕见病框架计划(RDF Initiative),旨在为患者人数少、数据有限的疾病建立适用的监管框架,使药物开发更具可预测性。目前约95%的罕见病患者没有获批治疗。BIO在FDA于10月28日举行的公开会议上提出了建议。
推荐理由
FDA启动罕见病监管框架计划,BIO在公开会议上提出建议,读者可了解该框架的出发点与行业诉求。
正文
The FDA has launched the Rare Disease Framework Initiative (“RDF Initiative”) to develop a fit-for-purpose regulatory framework to make drug development more predictable for conditions with small patient populations and limited data. Currently, about 95% of rare disease patients have no approved treatment.
BIO presented recommendations at FDA’s Oct. 28 public meeting. http://Bio.News has the details: https://bio.news/federal-policy/bio-supports-fdas-new-fit-for-purpose-rare-disease-framework-initiative/
来源:Biotechnology Innovation Organization · x.com